Clinical Trial

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
Protocol Amendment History 1 change
notable Trial sites expanded: 5 -> 9 locations 2026-07-11
Trial Details
NCT Number NCT07349537
Lead Sponsor Revolution Medicines, Inc.
Conditions Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC, NSCLC, Pancreatic Cancer +2 more
Enrollment 574 participants
Start Date 2026-01-08
Primary Completion 2028-04 (estimated)
Study Completion 2028-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-10